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ABSTRACT
Neurodegenerative diseases have a negative impact on health and economics,
effecting more than 20 million people in the United States and costing around $800
billion in 2018. Additionally, most neurodegenerative diseases such as Alzheimer’s
Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD),
and several others are fatal and have no cure or effective treatment. Many of these
diseases have a common theme of protein aggregates being present in disease tissue.
These aggregates are thought to be toxic to the cell and prevention of pathological
aggregation and elimination of these cellular aggregates may serve as a potential
therapeutic approach to treat disease. Furthermore, identifying a common mechanism
shared in all diseases that seeds the toxic aggregation of proteins would enable
therapeutic approaches that prevent protein aggregation to be more broadly applicable.
Here we demonstrate the ability of intrinsically disordered proteins found in
neurodegenerative diseases to undergo liquid-liquid phase separation and show that
this can seed their aggregation and lead to detrimental effects on the cell. We also show
that this behavior can be modulated by exploited ratios of expressed pathological
proteins as well as increasing the expression of chaperone proteins. This work offers
some key insight to a potential mechanism shared across several neurodegenerative
disease related proteins that could be targeted in order to alleviate disease progression.

v

Chapter One1:
Protein Liquid-Liquid Phase Separation in Neurodegenerative Disease
1.1 Abstract
Protein misfolding and misassembly are key molecular themes in many
neurological disorders. This aberrant protein behavior is found in disorders such as
Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Alzheimer’s
Disease (AD), and Huntington’s Disease [1] and leads to neuronal loss and cognitive
and motor impairments. Although protein aggregation is a well-accepted aberration in
these diseases, the challenge is to determine what is driving the process and what is
just simply a consequence of it. Many of the proteins found in pathological aggregates
in neurological diseases have the unique ability to undergo liquid-liquid phase
separation and are found in cellular membraneless organelles. Here we will discuss the
physiological role of liquid-liquid phase separation and membraneless organelle
formation. We will also discuss how sustained phase separation and membraneless
organelle formation can lead to protein aggregation and disease pathology.

_______________________
1Portions of this work were previously published (Darling, A.D. et al., 2018) and are used with

permission of the publisher.
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1.2 Introduction
Although pathological misfolding of proteins has been a key observation in
several neurodegenerative diseases, the exact mechanism that initially seeds the
aggregation has not been fully realized. While clues have been provided for why
particular proteins aggregate, there is not a general mechanism that explains most
cases. However, it has been shown that increasing the local concentration of protein
increases the propensity of the protein to aggregate [2]. Additionally, increasing protein
local concentration is the key driving factor for proteins to undergo liquid-liquid phase
separation (LLPS) with leads to the formation of membraneless organelles (MLOs)
inside the cell [3]. LLPS can result in a more confined space for the proteins contained
in the phase separated droplet and therefore increases their rate of aggregation if
droplet formation is sustained. Because of the connection of LLPS and protein
aggregation, it is conceivable that it may be an early step that seeds the aggregation of
proteins involved in the pathology of neurodegenerative diseases. Here we will discuss
the physiological role of LLPS and MLOs in cells and how they can become pathological
and lead to detriments in various neurodegenerative diseases.
1.3 Discussion
1.3.1 Aging and Disease
The primary risk factor for most neurodegenerative diseases is aging [4]. All
cells age due to a time dependent accumulation of cellular damage which leads to a
progressive decline in physiological functioning [5, 6]. In younger cells, the mechanisms
to repair the damage are viable therefore allowing the cell to overcome stress.
However, in aged cells, homeostasis mechanisms are weakened to the point where the
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cell is no longer able to repair itself when faced with insults. Therefore at its core, the
process of aging seems to result from a loss of homeostatic capacity but is associated
with several hallmarks including loss of proteostasis, genomic instability, mitochondrial
dysfunction, stem cell exhaustion, cellular senescence, and defective or deregulated
signaling [4]. The major problem currently faced is to discern the connection of these
aging hallmarks and figure out how they individually contribute to the overall process.
The cause for the deterioration of homeostatic mechanisms in aged cells is not
well understood. There are several concepts which have been proposed to explain this
phenomenon including a decline in metabolic activity [7-10], damage to biomolecules
such as protein and nucleic acids [11], and deregulated gene expression [12, 13].
However, the challenge is to determine what is driving the process and what is just
simply a consequence of it. Whichever the case, aging results in a universal decline in
cell health and it inevitably leads to the emergence of age-related diseases and death of
the organism.
During the process of aging, there are major fluctuations in the physical-chemical
parameters of the cell. This is driven by two factors. The first is a decline in metabolic
activity due to damage associated with the mitochondria [7, 8, 10] and the other is the
failure of homeostatic systems such as proteostasis [11]. Aberrations in these factors
lead to rapid changes in the cellular environment which can cause detrimental effects
on the ability of the cell to maintain intracellular organization and spatiotemporal control.
In fact, this concept may explain the multifaceted hallmarks of aging and the increase of
disease that accompanies it.

3

1.3.2 Membrane-less Organelles
Compartmentalization of biomolecules is essential for a cell to carry out its
biological functions and maintain intracellular organization. Physical separation is
achieved using compartments in the cell which are known as organelles. Some
organelles achieve separation using a membrane while others are known as
membraneless organelles [14]. Some examples of membrane bound organelles include
the nucleus, mitochondria, and chloroplast. MLOs form by spontaneous liquid-liquid
phase separation (LLPS) into multi-component viscous liquid structures [42]. The
phase-separation occurs due to changes in the cell environment that trigger molecular
supersaturation such as alterations in salt concentration, pH, and changes to protein
charge due to post-translational modifications [42]. The selective partitioning produces a
specialized chemical microenvironment that enables specific reactions to occur such as
the remodeling of nucleic acids [43] and ensures spatiotemporal control over
biochemical reactions that are diffusion-limited [15].
There are many kinds of MLOs in cells that perform a variety of functions, the
vast variety of organelles are shown in Figure 1.1. The localization and functioning of
some of the main organelles is shown in Table 1.1. The nucleus is a membrane bound
compartment but is further partitioned into MLOs such as the nucleolus and cajal
bodies, just to name a few [46]. The cytoplasm, mitochondria, and chloroplasts also are
sites of membrane-less organelles. The cytoplasm contains organelles that form
because of cellular stress such as stress granules. Many of these membraneless
compartments have been shown to have an association with age-related diseases
which showcases the vulnerabilities of these components during the aging process. For
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example, mutations associated with ALS are mainly in proteins that are prominent
members of membrane-less organelles such as TDP-43 and FUS [16-20]. Additionally,
there is increasing evidence showing that there are defects in membrane-less
organelles which are associated with protein misfolding diseases and cancer [21]. Some
of the most abundantly studies MLO’s will be discussed below.
Nuclear Pore Complex
In eukaryotic cells, the nuclear pore complex (NPC) is embedded in the nuclear
membrane and are the largest protein complexes in the cell, possessing a mass of ~125
megaDaltons (MDa) in vertebrates [22] and 66 MDa in yeast [23]. It functions to enable
the selective transport of molecular across the nuclear membrane. NPCs are large
molecular machines operated by proteins rich is phenylalanine and glycine domains
(FG domains) that are intrinsically disordered [24, 25]. Proteins with these domains can
form dense hydrogel-like phases allowed for the privileged passage of molecules
through the nuclear membrane [24, 25]. The FG domain proteins undergo spontaneous
phase separation into dense hydrogels that are permeable to the cargo of nuclear
transport receptors but act as effective barriers for macromolecules [25].
Nucleolus
In the nucleus the largest, and arguably most important, MLO is the nucleolus. It
is responsible for the assembly of ribosomal subunits, and perturbations in it led to
defects in ribosome assembly and translation [48]. The protein nucleophosmin (NPM1)
is the main component of the nucleosome and is required for its formation via phaseseparation [49]. Once formed, the nucleosome is dynamic, dissipating once ribosomes
are assembled to allow for their export [48]. Aberrations in the formation and dynamics
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of the nucleoli can lead to an overall decrease in global protein translation, something
that has been observed in several neurodegenerative diseases [25].
Cajal Bodies
Cajal bodies or coiled bodies, called so due to the presence of the protein coilin
which appears as coiled threads, are in the nucleus [26]. They have prominent
appearance in cells that are highly active such as neurons and cancer cells [27]. They
are functionally involved in assembling the U small nuclear ribonucleoproteins that are
required for spliceosome formation and are therefore assumed to increase the efficiency
of the complexes formation [26].
Paraspeckles
Paraspeckles are another nuclear membraneless organelles. They are involved
in the control of gene expression. The formation of paraspeckles occurs through phase
separation and is driven by the long non-coding RNA NEAT1, whose knockdown leads
to their rapid disintegration [28, 29]. Paraspeckles are the sight of several proteins that
are mutated in ALS such as TDP-43 and FUS [30], and therefore may have important
implications in the pathophysiology of the disease. For example, TDP-43
downregulation leads to the formation of paraspeckles by inducing the accumulation of
NEAT1 [31].
P-Granules
One of the early observations of membrane-less organelles was the discovery of
processing bodies (or P-granules), which are germ granules specific to Caenorhabditis
elegans. P-granules contain RNA granules and RNA binding proteins, mainly PGL1 and
PGL3 as well as DEAD-box proteins [1, 32]. These granules have been shown to
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segregate during the development of Caenorhabditis elegans germline and exhibit
liquid-like behavior [33]. The liquid-like behavior observed involves minimizing surface
area, droplet fusions, and flow-like features such as dripping in response to shear
stress, which can be explained by the fast-internal molecular rearrangements that occur
within P granules. Such rapid rearrangements are enabled by multiple weak interactions
between RNA molecules and the RNA-binding proteins present in P granules and
constitute a general principle of liquid compartments that partition the intracellular space
[33].
Stress Granules
When the cell is exposed to specific stressful events stress granules (SGs),
which contain untranslated messenger ribonucleoprotein (mRNP), form in the cytoplasm
[50]. The stressor halts translation and the aborted translation initiation complex can
either be routed to translation initiation or degraded [51]. The assembly of SGs is
mediated by the prion-like aggregation of TIA1, which causes it to be recruited into SGs
in all cell types [50]. Another SG protein component is a phosphorylation dependent
endoribonuclease known as RasGAP SH3-binding protein (G3BP) [51]. G3BP interacts
with RasGAP in its central domain, where it is dephosphorylated at serine 149, thus
recruiting it to SGs [51].
SG assembly is a dynamic process that resolves once the stress inducing insult
has been terminated, causing the SGs themselves to absolve [52]. However, in cases
where the insult is too large to overcome, SGs do not clear, and instead the cell
switches from a rescue path to a self-induced death pathway [50, 52]. Additionally, if the
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stress is sustained, but the cell finds a way to overcome death, it can lead to deleterious
effects on the cell later [20, 34]
‘Aging’ of SGs can lead to an increase in protein aggregation. In fact, data shows
that sustained SG formation leads to an increase in TDP-43 aggregation and
cytoplasmic mislocalization due to loss of mobility, both of which are hallmarks in ALS
[53]. Additionally, there is increasing evidence showing that aberrant formation of RNP
granules takes a central role in ALS and FTD. Many of the genetic mutations associated
with these diseases are in resident SG proteins, such as TIA-1, hNRNPA1, FUS, and
TDP-43 [1, 54]. In Alzheimer’s disease, stress granules are associated with tau
pathology and tau expression leads to poorly dynamic stress granules that are unable to
be cleared [35, 36].
1.3.3 Intrinsically disordered proteins and liquid-liquid phase separation
MLOs frequently contain protein molecules and RNA. The proteins that drive
phase transitions are referred to as intrinsically disordered proteins/regions (IDP/IDRP)
that contain low complexity domains (LCDs) consisting of repeat amino acids or short
amino acid motifs with an intrinsic preference for conformational disorder [42, 44, 45].
The amino acid composition of these proteins is often biased with low amino acid
diversity, having polar and charged groups favored [45]. The lack-of structure of
IDP/IDPRs is important for MLOs for many reasons. IDP/IDPRs have a conformational
flexibility that allows for the fluidity of MLOs and can form a multitude of transient
contacts allowing for the stability of the MLO once formed [46]. Once phase separation
occurs, the newly-formed MLOs exhibit hallmark behaviors of liquid such as classical
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wetting and dripping behaviors, sufficient surface tension to maintain a spherical shape,
fusion upon contact, and flow in response to shear stresses [47].
Since protein LLPS is extremely sensitive to the physical-chemical environment,
small fluctuations in the cell can lead to large changes in the formation and function of
MLOs. In-vitro studies have shown that changes to parameters such as protein
concentration, pH, ion and small molecule concentration, temperature, affinity of
macromolecules, and energy levels can have an effect of LLPS [37].
1.3.4 Prevalence of intrinsic disorder in proteins in membraneless organelles
All proteinaceous MLO’s contain specific sets of resident proteins. Several
studies have indicated that the presence of significant levels of intrinsic disorder
represents a characteristic feature of some of the proteins associated with
proteinaceous MLO’s 35-46 However, no systematic analysis of the intrinsic disorder
predisposition was conducted so far for the MLOs in the human proteome. To fill this
gap, we discuss below results of a systematic bioinformatics analysis of the disorder
status of 4796 human proteins from 20 PMLOs. These proteins were retrieved mostly
using the outputs of the QuikGO tool (https://www.ebi.ac.uk/QuickGO) complemented
with some literature search. The analyzed proteins were distributed among the human
PMLOs as follows: Nucleolus (1626) > Chromatin (1350) > Nuclear speckles (650) >
Centrosome (530) > Mitochondrial RNA granules (229) > PML bodies (104) > SGs (57)
> Perinuclear compartment (55) > CBs (54) > PcG bodies (48) > P‐granules (19) >
Nuage (18) > Cleavage bodies (14) > Gemini (10) > SAM68 bodies (8) > Paraspeckles
(6) > Nuclear SGs (5) = OPT domain (5) > HLB (4) = Neuronal RNP granules (4). This
list is not an exhaustive one nor does it contain all human MLO related proteins. In fact,
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a recently designed Cell Atlas representing a comprehensive image‐based map of the
subcellular protein distribution identified localization of 12003 human proteins to 30
subcellular structures assembled into 13 major organelles, such as nucleus (1922
proteins, together with nucleoplasm, nuclear speckles, and nuclear bodies containing
3739, 444 and 482 proteins, respectively), nucleoli (1016 proteins, together with fibrillar
center (254 proteins) and rim of nucleoli), nuclear membrane (272 proteins), Golgi
apparatus (959 proteins), endoplasmic reticulum (430 proteins), vesicles (1806 proteins,
together with lipid droplets containing 35 proteins), plasma membrane (1466 proteins,
together with cell junctions containing 285 proteins), mitochondria (1070 proteins),
cytosol (4279 proteins, together with cytoplasmic bodies (48 protein), aggresomes (17
proteins), and rods and rings (18 proteins), intermediate filaments (179 protein),
microtubules (263 proteins, together with microtubule ends (four proteins), cytokinetic
bridge (88 proteins), mitotic spindle (17 proteins), midbody (36 proteins), and midbody
ring (12 proteins), centrosome (336 proteins, together with the microtubule organizing
center containing 132 proteins), and actin filaments (223 proteins, together with focal
adhesions containing 133 proteins) [38].
Figures 1.2, 1.3, 1.4, and 1.5 represent the result of a global analysis of the
intrinsic disorder predisposition of 4796 human proteins associated with different MLOs.
To this end, first, we looked at their overall disorder levels (protein‐average disorder
scores, PADS) evaluated by three members of the PONDR family of disorder
predictors, PONDR® FIT,[39] PONDR® VLXT, [40] and PONDR® VSL2 [41-43].
Results of this analysis are summarized in Figure 1.2, where correlation between the
outputs of these three predictors are shown as 3D plot, and which illustrate that
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significant fractions of proteins in most human MLOs are noticeably disordered. This
conclusion is based on the consideration of the outputs of this analysis using the criteria
of accepted classification, where two arbitrary cutoffs for the levels of intrinsic disorder
are used to classify proteins as highly ordered (PADS ho < 0.25), moderately disordered
(0.25 ≤ PADSmd < 0.5), and highly disordered (PADS hd ≥ 0.5%) [44]. Figure 1.2 shows
that according to this classification, many proteins in almost all PMLOs are highly or
moderately disordered. By their disorderedness degree (PADSmd + PADShd) evaluated
by PONDR® FIT, human MLOs can be ranked as follows: nuage (33.4%) < P‐granules
(57.9%) < mitochondrial RNA granules (62.0%) < perinuclear compartment
(67.3%) < neuronal RNP granules (75.0%) < centrosome (81.5%) < nucleolus (81.9%) <
paraspeckles (83.3%) < nuclear speckles (87.8%) < gemini (90.0%) < PML bodies
(90.3%) < CBs (90.7%) < SGs (93.0%) < PcG bodies (93.7%) < chromatin
(95.5%) < cleavage bodies (100.0%) = SAM68 bodies (100.0%) = nuclear SGs
(100.0%) = OPT domain (100.0%) = HLB (100.0%). Analogous analysis conducted for
the entire human proteome (20228 proteins retrieved from the Consensus Coding
Sequence database [45-47] revealed that this set contains 3969 (19.6%), 5164 (25.5%),
and 11095 (54.9%) highly disordered (PADS hd ≥ 0.5%), moderately disordered
(0.25 ≤ PADSmd < 0.5), and highly ordered (PADS ho < 0.25) proteins, respectively. In
other words, according to their overall disorderedness degree (PADS md + PADShd)
evaluated by PONDR® FIT (45.1%), proteins of human proteome are noticeably less
disordered than proteins in all human MLOs (except for nuages). These data clearly
show that the proteome of MLOs is, in general, highly intrinsically disordered.
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1.3.5 Physiological consequences of protein phase separation
Protein phase separation is a physiological process used by the cell to reach
several goals. The formation of membraneless organelles due to phase separation can
tune reactions, organize the intracellular environment, and has a role in cellular fitness.
Each of these functions enabled by protein phase separation are discussed below.
Reaction tuning
Microdroplet chemistry has been used to accelerate reaction rates by several
orders of magnitude by providing a specific microenvironment to tune reaction rates
[48]. The same concept is true of membraneless organelles. Their phase-separation
behavior allows them to maintain a partitioned environment that can obtain conditions
that vary from the outside aqueous environment [37]. Specifically, phase separation
leads to an increase in the concentration of certain molecules. Because the reaction
concentrations of molecules have an impact on the reaction rate, higher concentrations
may lead to increases in rates of reaction within the enclosed space [49]. For example,
concentrating RNA into liquid droplets led to a significant increase in ribozyme’s
substrate cleavage activity [50]. Additionally, behavior like this has been observed
during the formation of cytoskeleton components, such as microtubules [51].
Additionally, the presence of absence of certain molecules can enable or disable
reactions to occur. Liquid droplets formed by phase separation in the cell can act as
filters to regulate which molecules can enter and exit, similar to membranes found on
more traditionally known organelles such as the nucleus. A common molecule that is
selectively allowed to enter MLO’s is RNA. The structure, length, and interactions of
RNA effect its ability to partition into phase separated droplets in the cell [52]. In fact, it
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was demonstrated that longer RNA species more effectively partition into phase
separated liquid droplets [50]. The ability of protein phase separation to tune reactions
could lead to the ability to artificially increase or decrease reactions in the cell which are
desirable or pathological. Therefore, finding out more about the mechanisms by which
membraneless organelles selectively partition molecules and the microenvironments
they are in is an important avenue that should be explored.
Intracellular Organization
One of the most important roles of phase separation in a cell is it enables the cell
to organize its intracellular environment. It does this through compartmentalization that
allows for specific biochemical reactions to occur, internal rearrangements, and the
selective diffusion of molecules in and out of the organelle [53].
Due to the large surface area of neurons, spatially confining molecules in certain
locations is important and they often utilize LLPS to aid in this process. For example,
neurons utilize LLPS in synaptic vesicles located at synapses as a method of
intracellular organization. It is used for the functional purpose of clustering replenishable
pools of synaptic vesicles during period of heightened synaptic activity [54]. Synapsin,
which is the mediator of synaptic vesicle clustering, undergoes LLPS which recruits the
vesicles into the clusters where they are more easily accessible [54].
Another example of neurons exploiting LLPS to achieve intracellular organization
lies in protein-rich compartments on the post-synaptic membrane which remodel protein
composition during long-term potentiation called postsynaptic densities [55]. These
protein-rich compartments are what underlie learning and memory. It was recently
proposed that the formation of post-synaptic densities occurs through LLPS of two
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protein components, SynGAP and PSD-95, allowing the neuron to locally concentrate
proteins without influencing global translation [56]. Because of the importance of cellular
organization, phase separation has a large physiological role and it can easily be
hypothesized that aberrations in the ability to maintain this intracellular organization
would have determinantal effects on the viability of the cell.
Cellular fitness
Strategies to increase cellular fitness are explored as potential treatments for
most diseases. Since phase separation is highly responsive to environmental changes,
it has the potential to be exploited to allow the cell to sense, respond to, and recover
from stress [53]. In other words, phase separation and the subsequent dissipation of
droplets may increase cellular fitness if it occurs at advantageous times. One challenge
that cells often incur is protein misfolding which leads to stress. This process can trigger
phase separation of membraneless organelles that can store and attempt to refold
proteins or push them for degradation to relieve the stressor [57]. For example,
disturbances in proteostasis an lead to the stalling of translation and the subsequent
formation of stress granules which contain protein and RNA. Misfolded proteins in
stress granules can then be clear by chaperone protein complexes [58], and eventually
the entire stress granule is dissipated by the Hsp70, Hsp40, and Hsp110 complex [59].
Therefore, the ability of a cell to respond to stress without pathological consequences
can be altered by the formation of membraneless organelles.
1.3.6 Pathological phase transitions in neurodegenerative diseases
Although protein phase transitions have several roles in the cell, changes in the
environment can cause physiological phase transitions to become pathological and lead
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to disease phenotypes. Here we discuss the pathological changes that can occur such
as changes in the internal dynamics, aberrant post translational modifications (PTMs),
and mutations.
Changes in internal dynamics of MLOs
Different phase-separated proteinaceous entities are characterized by physical,
dynamic, and mechanical properties that can vary in a broad range. Some of these
entities are highly dynamic liquid-like droplets [60-67], whereas others, such as balbiani
bodies, centrosomes, nuclear pores, and amyloid bodies, are much less dynamic
“bioreactive gels” with properties ranging from viscous liquids to gels and even to solidlike functional amyloids [68]. These non-dynamic “bioreactive gels” or “biomolecular
condensates” are not formed instantaneously. Instead, the very first step of their
biogenesis is the formation of dynamic, liquid-like droplets that quickly mature into much
less dynamic structures [68]. Furthermore, although many MLOs (e.g., SGs) are liquidlike in the norm, they can mature or age into much less dynamic state, typically coinciding
with the formation of fibrous structures [69]. Such maturation leads to changes in the
mechanical and physical properties of cellular bodies that can be of biological importance
[69]. Of great importance are recent observations that SGs are characterized by the
heterogeneous (or biphasic) structures containing a core, where the proteins are more
densely packed, and a more diffused shell favoring exchanges of constituents between
SGs and the surrounding cytoplasm [70]. Kinetically, these different SG phases are
formed at distinct stages of the SG biogenesis, with dense core being assembled at an
early event in granule assembly [70]. It was also indicated that the SG maturation and
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time-dependent changes in the dense core of this MLO can serve as a potential source
of insoluble protein aggregates [71].
Therefore, at least for some MLOs there is a specific time of existence before
pathology ensues, since aberrant biogenesis of PMLOs and their abnormal aging can be
accompanied by the misfolding and pathological aggregation of MLO-residing
IDPs/IDPRs, being related to the pathogenesis of various human diseases [20, 72, 73].
In other words, if the stress is sustained, but the cell finds a way to overcome death, this
can generate some deleterious effects on the cell later. In fact, ‘aging’ of SGs can lead to
an increase in protein aggregation, and data show that sustained SG formation results in
the increased aggregation and cytoplasmic mislocalization of Tar DNA Binding Protein43 (TDP-43) due to the loss of mobility, both of which are hallmarks in ALS [74]. Recently,
it was directly shown that pathological aggregation and fibrillation of low-complexity
domain (LCD) of TDP-43 was dramatically accelerated under phase separated
conditions, suggesting that aberrations in the process may contribute to pathogenesis in
neurodegenerative disease by promoting pathological TDP-43 aggregation [75].
Liquid droplets formed by the positively charged microtubule-binding domain of
intrinsically disordered microtubule associated protein tau were shown to undergo
coacervation with negatively charged molecules and this coacervation promoted amyloid
fibril formation [76]. In another study, soluble tau was shown to undergo LLPS under
cellular conditions, with resulting phase-separated tau droplets rapidly undergoing
transition to the gel-like species that eventually matured to amyloid-like fibrils, suggesting
that these droplets served as an intermediate toward tau aggregate formation [77].
Finally, many intrinsically disordered RNA-binding proteins (RBPs) possessing LCD
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domains that are aggregated in patients with different neurodegenerative diseases were
found in SGs, suggesting that the dynamics of SGs can be altered by inclusion of such
pathology-related proteins [78].
Aberrant PTMs and pathological phase separation
The activity of many proteins is regulated by various PTMs. Since PTMs represent
one of the sides of “biological dark matter” (which is composed of biologically important
protein species that are not amendable to structural characterization by traditional tools
developed to investigate ordered proteins [79]), and since many PTMs occur in IDPRs
(that themselves represent another component of the ‘dark matter of biology’), it was
indicated that such disorder-centered PTMs constitute the darker side of the biological
dark matter [80]. Altogether, by extending the range of structures and physico-chemical
properties of amino acids, PTMs play important roles in the increase in the variability and
diversity of protein structures and functions [81]. In fact, due to the variability of PTMs,
the actual number of chemically different amino acids typically utilized in protein
biosynthesis increases from 20 to more than 140, and as many as 300 different PTMs
can be found in proteins [82].
PTMs changes protein structure at many different levels by covalently adding
various chemical groups (such as different small molecules, carbohydrates, lipids, and
even entire proteins or nucleic acids) to amino acid side chains, or removing various
chemical groups, or via enzymatic cleavage of peptide bonds. Since different PTMs can
differently affect physicochemical properties of a protein [83], different modifications can
graft different functions to the same protein [84]. Although natural variability of PTMs is
very broad, these modifications are typically very specific. Many PTMs are catalyzed by
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special enzymes that recognize motifs in target sequences of specific proteins. Some
PTMs (e.g., phosphorylation, acetylation, glycosylation, lipidation, methylation, and
nitration) are readily reversible due to the concert action of modifying and demodifying
enzymes. Such and interplay between the conjugating and deconjugating enzymes
represents an economical and rapid way of the controlling the protein function.
Furthermore, although mutations (which represent another means of changing the
chemical properties of a polypeptide chain) can only occur once per position, different
forms of PTMs may happen in tandem [85]. Since PTMs represents crucial means for the
regulation of protein structure and function, deregulation of PTMs is commonly associated
with the development of various pathological conditions [80, 86, 87]. Therefore, it is not
surprising that aberrant PTMs can affect disorder-based LLPSs and MLOs.
An illustrative example of this concept is given by poly(ADP-ribosylation)
(PARylation), one of the PTMs associated with neurodegeneration [88]. PARylation is a
reversible enzymatic attachment of multiple NAD-derived ADP-ribose (ADPr) units to
target proteins. PARylation is catalyzed by a family of PARP enzymes [89, 90], whereas
dePARylation is conducted by the hydrolyzing

enzyme poly(ADP-ribose) (PAR)

glycohydrolase (PARG) [91, 92]. Furthermore, some proteins are capable of non-covalent
PAR-binding [93]. In addition to numerous physiological roles of PARylation that range
from gene expression to DNA repair, mitochondrial biogenesis, neuroinflammation, and
regulation of a variety of signaling pathways inducing different forms of cell death,
alterations in this PTM were associated with aberrant phase transitions and pathological
aggregation of several proteins associated with Alzheimer’s disease (AD), Parkinson’s
disease [1], Huntington disease [38], and amyotrophic lateral sclerosis (ALS), such as α-
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synuclein, TDP-43, and heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) [88].
Since PAR is characterized by a multivalent anionic polymeric structure resembling
nucleic acids, and since many neurodegeneration-related proteins are RBPs that also
contain the PAR-binding motifs (PBM), increased levels of PAR can directly influence
amyloid aggregation of some PBM-containing proteins or modulate phase transitions in
other pathology-associated RBPs, such as TDP-43 and hnRNPA1 [94], or stimulate
association of some of these RBPs with SGs [88]. The picture is further complicated by
the fact that hnRNPA1 can be PARyated, and this PTM facilitates the phase transition of
hnRNPA1 alone and stimulates the co-phase-transitions of TDP-43 and hnRNPA1 [95].
Additionally, the LCD of RNA-binding protein hnRNPA2B1 (heterogeneous nuclear
ribonucleoprotein A2B1) can undergo LLPS and promotes hnRNPA2B1- TDP-43 cophase separation, the arginine methylation of this domain reduces the efficiency of
hnRNPA2 phase separation and inhibited co-phase separation of this protein with TDP43 [96].
The AD related intrinsically disordered microtubule-associated protein tau is
known to undergo liquid-liquid phase transitions [76], efficiency of which can be affected
by various mutations and PTMs, such as truncation, hyperphosphorylation,

and

hyperacetylation [76, 97]. Importantly, these different factors differently affected the phase
transition behavior of tau, with truncation, mutation, and hyperphosphorylation enhancing
tau phase transitions and aggregation [76], and with hyperacetylation disfavoring phase
transitions and inhibiting the heparin-induced aggregation of this protein [97].
Mutations and pathological phase separation
Biogenesis of MLOs can be affected by pathological mutations in proteins either
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undergoing LLPS or proteins involved in MLO regulation. For example, different
properties of SGs, such as their number, mean size, lifespan and internal dynamics, as
well as the SG capability to control stress suppression are all affected by TDP-43 with
ALS-related point mutations [98, 99]. Similarly, biogenesis of SGs (namely, kinetics of
their assembly and disassembly) is affected by ALS-related point mutations in FUS, which
becomes

incorporated

into

SGs

[100].

Similarly,

heterogeneous

nuclear

ribonucleoproteins (hnRNPs) A2B1 and A1 (hnRNPA2B1 and hnRNPA1) with ALSrelated point mutations in their prion-like domains noticeably alter SG biogenesis and
dynamics, being excessively incorporated into this MLO [101]. On the other hand, ALSrelated point mutations in T-cell-restricted intracellular antigen-1 (TIA1) were not only
impact the SG dynamics but also promoted the accumulation of stable SGs that contained
TDP-43 [74]. Systematic analysis of several familial ALS-related point mutations in the
proteasomal shuttle factor UBQLN2 mostly affecting the proline-rich (Pxx) region of this
protein revealed that the UBQLN2 LLPS was differently affected by these ALS-linked Pxx
mutations [102]. This differential effect was dependent on the type and sequence position
of a given amino acid substitution, suggesting that ALS-linked Pxx mutations altered
physical properties of UBQLN2, modified the in vivo behavior of this protein, and
contributed to the aberrant morphology and dynamics of SGs, eventually resulting in the
appearance of ALS specific inclusions [102].
It was shown that the unnatural dipeptide repeat (DPR) proteins (poly(glycinealanine),

polyGA;

poly(glycine-arginine),

polyGR;

poly(proline-alanine),

polyPA;

poly(proline-arginine), polyPR; and poly(glycine-proline), polyGP) generated as a result
of the hexanucleotide (GGGGCC) repeat expansion in the gene chromosome 9 open
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reading frame 72 (C9ORF72), which is considered now as the most common genetic
cause of ALS and frontotemporal dementia (FTD), were able to alter the liquid-like state
of PMLOs [103]. Furthermore, arginine-rich DPRs (polyGR and polyPR) were shown to
undergo LLPS themselves and were able to efficiently induce phase separation of a large
set of proteins related to the RNA metabolism and SG biogenesis [104].
1.4 Conclusions
LLPS and the formation of MLOs is extremely important to maintain cellular fitness.
Since the phenomenon is so sensitive to the conditions of the environment, the
physiological functions can easily be affected by changes that naturally occur due to aging
and disease. These changes can lead to pathological LLPS and membraneless
organelles that lose the ability to dissipate. Loss of dynamics has been shown to lead to
the pathological aggregation of proteins, something that is a common phenomenon seen
in neurodegenerative disease. Therefore, maintaining or restoring the dynamics of
pathological MLO’s may be an enticing avenue for therapeutic endeavors.

.
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Figure 1.1 Diversity of membraneless organelles found in eukaryotic cells.
Schematic representation of the multitude of cytoplasmic, nuclear, mitochondrial, and
chloroplast membraneless organelles.
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Figure 1.2 Abundance of intrinsic disorder in human PMLO‐related proteins A) and in
human proteome B). In both plots, consensus 3D PONDR® FIT vs. PONDR® VSL2 vs.
PONDR® VLXT plot representing the correlation between the disorder content in
human PMLO‐related proteins A) and in human proteome B) evaluated by PONDR®
VLXT (X‐axis), PONDR® VSL2 (Y‐axis), and PONDR® FIT (Z‐axis). Following the
accepted practice, two arbitrary cutoffs for the levels of intrinsic disorder are used to
classify proteins as highly ordered (PADSho < 0.25), moderately disordered
(0.25 ≤ PADSmd < 0.5) and highly disordered (PADShd ≥ 0.5%). The values in brackets
show the content of highly disordered, moderately disordered, and highly ordered
proteins in each PMLO A) or in human proteome B). Data for the human proteome
(20 228 proteins) were retrieved from the Consensus Coding Sequence database.
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Figure 1.3 Evaluation of the overall disorder levels and peculiarities of disorder
distribution in human proteins associated with PMLOs. A) Spread of the protein‐
average disorder scores in individual PMLOs evaluated by PONDR® VSL2 (black bars),
PONDR® VLXT (red bars), and PONDR® FIT (green bars). Bars show mean protein‐
average disorder scores in corresponding PMLOs, whereas error bars reflect the
corresponding standard deviations calculated by SigmaPlot software. B) Box‐and‐
whisker plot representing statistical analysis of the commonness of long IDPRs in
human proteins associated with various PMLOs. In this plot, the top of each box
indicates the third quartile, a horizontal line near the middle of the box indicates the
median, and the bottom of the box indicates the first quartile. A vertical line extending
from the top of the box indicates the maximum value, whereas a vertical line extending
from the bottom of the box indicates the minimum value. Black circles represent outliers.
Boxes without whiskers correspond to the PMLOs with small number of proteins (4–8).
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Figure 1.4 Finding potential disorder‐based protein–protein interactions sites in
human MLO‐related proteins. Analysis performed using the α‐MoRF‐Pred I (A and B),
α‐MoRF‐Pred II (C and D), and ANCHOR algorithms (E and F). For all three tools, data
are aggregated to show predicted binding regions per protein (plots A, C, and E) and
predicted binding residues per residue (plots B, D, and F). In these plots, horizontal bars
correspond to median values, whereas error bars show 2.5 percentile and 97.5
percentile, all estimated by 100 000 bootstrap iterations. Between 2.5 and 97.5 is the
95% confidence interval on the median.
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Figure 1.5 Evaluating global intrinsic disorder predisposition of all human
proteins A) and human proteins associated with various PMLOs B) by combining the
outputs of binary disorder classifiers, CH‐plot and CDF. Here, the coordinates of each
point were calculated as a distance of the corresponding protein in the CH‐plot from the
boundary (Y‐coordinate) and an average distance of the respective CDF curve from the
CDF boundary (X‐coordinate). The four quadrants correspond to the following
predictions: Q1, proteins predicted to be disordered by CH‐plots, but ordered by CDFs;
Q2, ordered proteins; Q3, proteins predicted to be disordered by CDFs, but compact by
CH‐plots (i.e., putative molten globules or hybrid proteins); and Q4, proteins predicted to
be disordered by both methods.
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Organelle

Location

Size (µm)

Known Function

Nuclear pore
Nucleolus
Cajal bodies
Paraspeckles
P-bodies
Stress Granules

Nucleus
Nucleus
Nucleus
Nucleus
Cytoplasm
Cytoplasm

0.1-0.2
0.2-3.5
0.1-2
0.2-1
0.1-0.3
0.1-0.3

Transport of molecular across nuclear envelope
Ribosome biogenesis
Regulation of snRNP maturation
Regulation of gene expression
Decay and processing of mRNA
Store tranlationally stalled ribonucleoproteins

Table 1.1 Examples of some membraneless organelles and their location, size,
and function.
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Chapter Two2:
Protein Liquid-Liquid Phase Separation in ALS/FTD
2.1 Abstract
A microsatellite expansion mutation in C9orf72 is the most common genetic
cause of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The
expansion mutation leads to C9orf72 loss of function, RNA foci, and five species of nonAUG RAN translated dipeptide repeat proteins (GA, GP, GR, PA, and PR). More than
one peptide species can be present in the same cell in a patient with the expansion,
however the interplay between the different species has not been established. Here we
determined that PR causes cytotoxicity, induces the spontaneous formation of poorly
dynamic stress granules, and phase separates with bound RNA. However, cotransfection of PR and GA ablates the cytotoxicity of PR alone and absolves the
appearance of spontaneous stress granules. In addition, we showed that the interaction
between synthetic GA and PR polypeptides leads to the formation of a protein complex
which is structurally and biochemically distinct from the individual comprising
components. Thus, the combined expression of distinct C9orf72-derived dipeptide
repeat species produces cellular outcomes and structural differences that are unique
compared to the expression of a single species.
_______________________
2Portions of this work were previously published (Darling, A.D. et al., 2018) and are used with

permission of the publisher.
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2.2 Introduction
An increasing number of neuromuscular and neurodegenerative disorders are
being classified as microsatellite expansion disorders due to the pathological link to
genetic mutations in specific microsatellite regions. These regions consist of tandem
DNA repeats that are prone to strand slippage during replication, which leads to the
addition or deletion of repetitive segments and a high level of length variation in repeat
sequences among individuals [105]. Strand slippage can lead to the accumulation of
large repetitive elements in the genome which can cause pathology via three separate
mechanisms. Expansions can lead to a loss of function in the gene that it is located
within, production and accumulation of toxic RNA species that sequester RNA-binding
proteins, and a gain of novel toxic function from the translation of aberrant polypeptide
species [106].
Two diseases with pathology driven by microsatellite expansions include
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). A link
connecting these two disorders was discovered when two groups identified a
hexanucleotide repeat expansion [107] in the 5’ non-coding region of the gene C9 open
reading frame 72 (C9orf72) gene [108, 109]. The discovery of the link between the two
diseases has led to the intensive investigation to determine how this aberration leads to
pathology and the possibilities are shown in Figure 2.1. After the genetic link was
discovered, two groups identified aggregation-prone dipeptide repeat (DPR) proteins
GA, GP, and GR in CNS tissue from patients with the C9orf72 expansion mutation [110,
111]. Later, it was determined that the antisense species can also be translated leading
to the discovery of PA, PR, and PG polypeptides [112]. The absence of a start codon

29

indicates these dipeptide species are most likely by repeat-associated non-ATG (RAN)
translation [112].
Although six DPR species are translated because of C9orf72’s HRE, the
biochemical differences between these peptide species causes them to behave
differently in cells and produce diverse cytotoxic outputs. The arginine-rich polypeptides
GR and PR, which are highly charged, have been shown to be the most toxic species in
Drosophila, yeast, and mammalian primary neurons [113-117], whereas GA is able to
form toxic amyloid species that can be spread between cells and cause toxicity [118,
119]. However, the exact mechanism by which DPRs cause cell toxicity remains
unclear. Studies conducted to examine the cellular effects of DPR expression primarily
focus on the effects driven by the expression of a single DPR. However, both sense and
anti-sense RNA foci for C9orf72 expansions have been identified in the same cell;
suggesting that multiple DPRs can be translated simultaneously [120, 121]. The
phenomena of multiple DPR expression was recently explored in a report which
identified GA as the most abundant DPR expressed in the frontal cortex of patients with
expanded C9orf72 and that GA could sequester other DPRs [122]. However, additional
studies are necessary to more thoroughly evaluate the cellular effects of DPR coexpression.
Here we examined the toxicity produced by individual DPR expression. We
identified PR as the most toxic DPR species in cell models capable of modulating the
behavior of membraneless organelles. Since GA was suggested to be the most
prominent DPR species, we then investigated potential interactions between PR and
GA. We showed that expression of GA can ablate PR-driven toxicity. We determined
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that the combination of GA and PR reduced markers of ER stress and lowered the
number of stress granules present. We then demonstrate that the altered toxicity is
likely due to significant structural changes which sequester PR and GA. Our data
illustrates the complex biological interactions that occur when multiple DPR variants are
simultaneously expressed and highlights the need for further investigative studies into
how DPR expression affects the disease state.
2.3 Materials and methods
2.3.1 Cell Culture and Transfection
NSC34, HEK293T, and HT22 cells were cultured in DMEM with 10% FBS and
kept at 37°C with 5% CO2. NSC34 and HT22 transfections were performed using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. PEI transfection was used for the HEK293T cells. The DPR-containing
plasmids used to transfect cells included pEGFP-GA(50), pEGFP-GP(47), pEGFPGR(50), pEGFP-PA(50), and pEGFP-PR(50) and were all generous gifts from Dr.
Leonard Petrucelli (Mayo Clinic, Jacksonville, FL). Other plasmids used included
pCDNA3.1-p62-HA and pEGFP-C-1 (Clontech, Mountainview, CA).
2.3.2 Primary Neuron Preparation and Transfection
All procedures involving the experimentation on animals were done in
accordance with the guidelines set forth by the Institutional Animal Care and Use
Committee of the University of South Florida. Cortico-hippocampal neurons were
prepared using a previously developed protocol [123]. Briefly, P0 mouse pups were
extracted from the womb, their brains were removed, cortices dissected in cold isotonic
buffer, washed, digested in trypsin, triturated, and resuspended in DMEM supplemented
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with 10% FBS and Antibiotic-Antimycotic Solution (Fisher Scientific, Waltham, MA). The
cells were then plated on poly‐l‐lysine (1:5; Sigma, St. Louis, MO) coated coverslips. 24
hours after plating, the media was changed to Neurobasal medium (Invitrogen,
Carlsbad, CA) supplemented with B27 (Life Technologies, Carlsbad, CA) and Glutamax
(Life Technologies, Carlsbad, CA). Neurons were transfected using Lipofectamine LTX
(Fisher Scientific, Waltham, MA) according to the manufacturer’s instructions.
2.3.3 Antibodies
The following primary antibodies were used in this study: p-PERK (Thr 981)
(1:500 Western blot, 1:200 immunofluorescence, Cat. sc-32577, Santa Cruz, Dallas,
TX), PERK (C33E10) (1:1000, Cat, 3192S Cell Signaling, Danvers, MA), AntiC9ORF72/C9RANT (poly-GA) (1:1000 Western blot, 1:200 immunofluorescence, Cat.
MABN889, EMB Millipore, Billerica, MA), Anti-C9ORF72/C9RANT (poly-PR) (1:1000
Western blot, 1:200 immunofluorescence, Cat. ABN1354, EMB Millipore, Billerica, MA),
TIA-1 (1:200 immunofluorescence, Cat. Sc-1751, Santa Cruz, Sallas, TX),
SQSTM1/p62 (cat. 5113, Cell Signaling, Danvers, MA), GFP Tag Antibody (1:1000, Cat.
G10362, Invitrogen, Carlsbad, CA), and Actin (1:1000, Cat. A2066, Sigma, St. Louis,
MO). Secondary antibodies used include Alexa-Fluor fluorescently labelled secondary
antibodies (1:500, Invitrogen, Carlsbad, CA) and horseradish-peroxidase linked
secondary antibodies (1:1000, Southern Biotech, Birmingham, AL).
2.3.4 Cell Staining and Imaging
NSC34, HT22, and primary neurons were prepared for staining 24 hours post
transfection. Cells were washed with 1× PBS, fixed in 4% paraformaldehyde (w/v) at
room temperature for 20 minutes, and then permeabilized for 10 minutes with 1× PBS
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containing 0.1% of Triton X-100. Cells were then blocked with 1× PBS containing 10%
goat or donkey serum (Lampire Biological Laboratories Inc. Pipersville, PA). Primary
antibody incubations were performed overnight at 4°C, and secondary antibodies were
incubated for 1 hour at room temperature. DAPI was added at a concentration of 1:5000
in 1× PBS for 5 minutes at room temperature. The cover-slips were mounted onto glass
slides using Prolong Gold mounting reagent (Life Technologies, Carlsbad, CA). An
Olympus FluoView FV10i confocal microscope equipped with a 60× UIS2 SAPO
objective was used for imaging. Quantitative analysis was performed using ImageJ
software (National Institutes of Health).
2.3.5 Peptide Staining and Imaging
0.5 µg of the peptides were added to cover-slips coated with 0.2% electron
microscopy grade glutaraldehyde (Electron Microscopy Services, Hatfield, PA) for 2hours at room temperature. They were then washed with 1x TBS, blocked with 1% BSA
in TBS overnight at 4°C, incubated with the primary antibody for 1-hour at room
temperature, washed with TBS, and then incubated with the secondary antibody for 1hour at room temperature. The coverslips were then mounted and slides were imaged
as described above.
2.3.6 Western Blotting
Cells were lysed using RIPA protein extraction reagent (50 mM Tris pH 7.4,
150 mM NaCl, 2 mM ethlenediaminetetraacetic acid (EDTA), 1% NP-40, 0.5% sodium
dodecyl sulfate) containing 1mM of PMSF as well as a protease inhibitor mixture
(Sigma, St. Louis, MO). 40 µg of the total extracted protein was run on 5-15% gradient
SDS-PAGE gels (Bio-Rad, Hercules, CA). The protein was then transferred to a PVDF
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membrane (Amersham Biosciences, Little Chalfont, United Kingdom), blocked with 7%
nonfat milk for 1 hour, incubated with the primary antibody overnight at 4ºC, and then
incubated with the secondary antibody for 1 hour at room temperature. ECL (Fisher
Scientific, Waltham, MA) was used to develop blots imaged using a LAS-4000 mini
imager (GE Healthcare, Little Chalfont, United Kingdom). ImageJ software (National
Institutes of Health) was used to perform densitometry and samples were normalized to
the loading control.
2.3.7 Recombinant Protein Production and Purification
A 50-repeat PR plasmid was synthesized by Genscript (Piscataway, NJ) in a
pet22b vector with a C-terminal GB1 solubility tag. The 50-repeat GA plasmid was in the
pGEX6P.1 vector and was a generous gift from Dr. Leonard Petrucelli (Mayo Clinic,
Jacksonville, FL). E. coli BL21 cells were transformed with the plasmids above then
grown at 37°C in LB media containing 100 μg/mL carbenicillin. Once their OD600
reached 0.8 the cells were induced with 1mM of IPTG (Gold Biotechnology, Olivette,
MO) for 2 hours. Centrifugation at 5,000 g for 15 min was used to harvest the cells,
which were then resuspended with either 1× PBS (GA 50) or Nickel chromatography
running buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM Imidazole) (PR50)
containing protease inhibitors. The cells were then lysed using a freeze-thaw cycle
followed by sonication. The lysed cells were centrifuged at 50,000 g for 1 hour at 4°C.
The GA50 supernatant was affinity purified using a standard gravity column packed with
Glutathione Agarose Resin (Fisher Scientific, Waltham, MA), while PR50 affinity
purification was performed using a HisPur™ Ni-NTA Resin (Fisher Scientific, Waltham,
MA). The eluted fractions were dialyzed into 1× PBS overnight and concentrated using
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an EMD Millipore Amicon™ Ultra-15 Centrifugal Filter Unit (Fisher Scientific, Waltham,
MA).
2.3.8 Peptide Synthesis
The GA20 and PR20 polypeptides were synthesized by DgPeptidesCo., LTD
(Hangzhou, China) using the following amino acid sequences:
GA(20):N’GAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA
GAWDYKDDDDK
PR(20):N’PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRWYP
YDVPDYA
Aromatic residue (tryptophan) was added at the C-terminal regions of the synthesized
peptides to simplify their spectroscopic analyses. Distinct C-terminal tags, FLAG
(DYKDDDDK; GA 20) and hemagglutinin (YPYDVPDYA; PR20), were added to each
DPR.
2.3.9 Isothermal titration calorimetry (ITC)
Solution of the poly-GA polypeptide (10 µM) in PBS (10 mM phosphate, 150 mM
NaCl, pH 7.5, 1.7 ml) was placed in the sample cell of the VP-ITC calorimeter (Malvern
Instruments) and incubated at 25 °C. A solution of the poly-PR polypeptide (20 µM) in
the same buffer was added (19 injections, 15 µl each) and ITC measurements
performed. Data was analyzed with Origin software.
2.3.10 Circular dichroism (CD)
Far-UV CD (190–260 nm) spectra of synthesized polypeptides were measured
using a JASCO J-815 spectropolarimeter at 25 °C. A solution of polypeptide (250 l, 0.1
mg/ml) in the appropriate buffer (10 mM) was incubated for 1 h at 25 °C, placed into a 1
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mm pathlength cell, and the CD spectra were acquired with 10 nm/min scan speed at
0.2 nm step size and 1.0 nm bandwidth under constant purging with nitrogen. Two
spectra were accumulated and averaged for each sample. Spectra in the presence of
0.15 M NaCl were measured in the 0.2 mm path-length cell at 0.5 mg/ml protein
concentration (60 µl sample volume).
Buffers used were citrate (pH 2.0-3.0), acetate (pH 4.0-5.0), phosphate (pH 6.0-7.5),
Tris (pH 8.0) and borate (pH 9.0-10.0). The same buffers were used for CD,
fluorescence and DLS measurements.
2.3.11 Fluorescence spectroscopy
The solution of synthesized polypeptide (13.3 µl, 1 mg/ml stock solution, 5 µg/ml
final concentration) was mixed with buffer (final volume 400 µl, final buffer concentration
10 mM). The solution was incubated for 1 h at 25 °C, and the intrinsic protein
fluorescence was measured. Excitation wavelength was 280 nm and emission spectrum
was recorded in the 295-380 nm range. Excitation and emission slits were at either 2.5
or 5 nm. The measurements were performed in duplicate for each sample.
2.3.12 Dynamic light scattering (DLS)
100 μl of the synthesized polypeptide solution (0.1 mg/ml) in the appropriate
buffer (10 mM) was placed in the well of the 96-well clear bottom plate (Corning,
Corning, NY), and dynamic light scattering was measured. DynaPro plate reader (Wyatt
Technology, Goleta, CA) equipped with an 830 nm laser and a temperature control
module. Ten 30-s measurements were taken for each well, and the measurements were
performed in duplicate. The Dynamics software (Version 7.0.1, Wyatt Technology
Corporation) was used for scheduled data acquisition and analysis.
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2.3.13 Nanoparticle tracking analysis
Samples were diluted 500-fold into 1 mL of 0.02 μm filtered de-ionized water.
Approximately 300 μl of sample was loaded onto the Malvern Nanosight LM10 equipped
with a 633 nm red laser. Protein particle data were captured with a Marlin CCD camera
in duplicate. Graphs were generated by Nanosight software.
2.3.14 Transmission electron microscopy
100 μM of each recombinant GA 50, PR50, and GA50+PR50 was adsorbed onto
prewashed 200 mesh formvar/carbon-coated copper grids for 5 min. The grids were
washed with water (10 μl), stained with filtered 2% uranyl acetate (10 µl) for 1 min and
washed with water again. The samples were analyzed with a JEOL 1400 Digital
Transmission Electron Microscope, and images were captured with a Gatan Orius widefield camera at the Electron Microscopy Core Facility in the College of Medicine at the
University of South Florida.
2.3.15 Image Analysis and Statistics
Quantitative analysis was performed using ImageJ software (National Institutes
of Health). The statistical significance performed for each analysis was done using
ANOVA with Tukey post tests for group comparison as well as Student’s t-tests.
2.4

Results

2.4.1 Co-Expression of PR with GA Alters the Localization, Cytotoxic Output, and
Morphology of PR
We began by characterizing the cytotoxicity of each individual DPR in a cell
culture system. Expression of PR50 was the most potent reducer of cell viability, though
each DPR reduced cell viability relative to the control transfection (Figure 2.1A). Since
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PR50 showed the highest toxicity, we examined if the co-expression of the most
abundantly expressed DPR, GA 50, altered the effects of PR50, similar to the
sequestration of other DPRs by GA, as previously reported [122]. To examine this, we
expressed GA 50 alone or in tandem with an increasing amount of PR50. GA50 ablated
PR50 toxicity when expressed at ratios of 10:1 and 5:1 (GA 50:PR50) (Figure 2.1B). We
found this result surprising due to precedent in the literature for GA presenting cellular
toxicities [118, 119, 122].
Next, we noticed that PR50 was always expressed in the nucleus, but GA 50 was
cytoplasmic (Figure 2.1C). We wanted to see if the localization of PR50 was altered
because of co-expression with GA 50. We found that when PR50 and GA50 are coexpressed, it results in a significant change to the localization of PR50 with a strong
reduction in nuclear species (Figure 2.1C and 2.1D).
2.4.2 PR expression leads to PERK phosphorylation and the spontaneous
formation of stress granules, GA rescues effect
Since the co-expression of GA 50 with PR50 rescued PR50-driven cytotoxicity, we
examined other PR-associated cellular stresses to identify the cell stress mechanism
being ablated by GA co-expression. Specifically, we were interested in looking at the
PERK pathway of the unfolded protein response due to the fact that other diseaserelated repeat peptides induce cell death in this manner [124]. We found that expression
of PR50 in HEK293T cells (Figure 2.2A) and primary neurons (Figure 2.2C) increased
PERK phosphorylation; a cellular event associated with a response to cellular stress,
which can trigger apoptosis [125]. The expression of the other DPR species did not lead
to any significant differences in the levels of phosphorylated PERK as compared to the
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control, apart from PA 50. We then wanted to see if the increase in PERK
phosphorylation produced by PR50 expression could be altered by co-expression with
GA50 in primary neurons. We co-transfected primary neurons with GA 50 and PR50, then
immunostained these cells for p-PERK. We found that co-expression of GA with PR
significantly decreased phosphorylated PERK levels compared to PR50 alone (Fig. 2.2C
and 2.2 D).
The phosphorylation of PERK is an event that occurs and can trigger stress
granule formation. Since literature has shown that expression of PR50 can lead to
aberrations in stress granules, we wanted to explore this. To do that, we expressed
PR50 alone or in combination with GA 50 then used immunostaining of TIA-1, a resident
stress granule protein, to quantify the number and size of stress granules. We found
that expression of PR50 was able to significantly increase the spontaneous formation of
stress granules but did not change the size (Figure 2.3A and 2.3B). Additionally, we
found that co-expression with GA 50 resulted in a rescue of this effect (Figure 2.3A and
2.3B).
2.4.3 GA and PR Interact and Co-Localize in a Cell-Free Environment
We then speculated that the ablation of PR50 toxicity was due to DPR
sequestration driven by structural changes. To examine this, PR50 and GA50 were
incubated separately or together in the 5:1 ratio observed to reduce PR 50 toxicity. Using
transmission electron microscopy (TEM), we observed that the combination of PR50 and
GA50 presented a structure distinct from either individual DPR (Figure 2.4A).
The observed structural/morphological uniqueness of the PR and GA
combination prompted us to characterize this interaction further. To more efficiently
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address structural issues, 20-repeat GA and PR peptides were synthesized (GA 20 and
PR20). A tryptophan residue was added near each C-terminus and distinct C-terminal
tags, FLAG (DYKDDDDK; GA20) and hemagglutinin (YPYDVPDYA; PR20), were added
to each DPR. We first utilized isothermal titration calorimetry (ITC) to monitor binding of
GA20 and PR20. After optimization of assay conditions, we found that these polypeptides
interacted at ~5:1 GA to PR ratio at pH 7.5 in the presence of 150 mM NaCl (Figure
2.4B).; the same ratio at which GA negated PR toxicity in our cellular experiments and
we observed a dramatic morphological change. The binding between GA and PR had a
high affinity with a binding constant ~100 nM and was favored both enthalpically and
entropically. This binding affinity is similar to that observed for binding of proteins to
other highly charged biopolymers, such as heparin [126]. We then performed peptideimmunostaining to confirm peptide interaction following co-incubation. Peptide
immunostaining demonstrated that the GA 20 and PR20 peptides do co-localize in a cell
free environment (Figure 2.4C). (Rcoloc=0.830).
2.4.4 Co-Incubation of PR with GA Leads to Structural Changes in Synthetic
Polypeptides
To further characterize the structures formed by the interaction of GA and PR, we
used dynamic light scattering (DLS) to examine the particle sizes of GA, PR, or the
combination of GA and PR. Particle size analysis revealed that co-incubation of GA 20
and PR20 produced particles larger than either individual DPR (Figure 2.5A). As a
supplement to these DLS results we used nanoparticle tracking analysis to follow
protein aggregation by directly observing protein aggregates with light microscopy and
tracking their Brownian motion [127]. Similar to our DLS observations, we recorded
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different populations of aggregates of various sizes for individual polypeptides.
However, the nanoparticle tracking analysis of co-incubated GA 20 and PR20 reported
that the resulting aggregates were larger in size and occurred at a higher frequency
than either individual peptide (Figure 2.5B). These results supported the presence of an
interaction between GA 20 and PR20 in a cell-free environment.
Next, we examined the secondary structure of these peptides using far-UV
circular dichroism (CD) spectroscopy. We measured far-UV CD spectra of GA 20 and
PR20 individually and in combination at physiological pH and salt concentrations to
determine whether interaction results in structural changes. We found that a spectrum
of GA20 has a minimum at 215-217 nm, which is typical for the proteins with β-sheet rich
structures (Figure 2.5C). Spectra of PR contained a minimum at 198-200 nm typical for
highly disordered polypeptides (Figure 2.5C). Spectra of the mixtures of these
polypeptides contained both spectroscopic bands as expected. To determine whether
structural changes occurred upon mixing of the polypeptides, the spectra of individual
polypeptides were subtracted from the spectrum of their mixture (Figure 2.5C; dashed
line). The results indicated that there is a loss of β-sheet structure and appearance of
disordered structure upon mixing (Figure 2.5C), which is an additional indication of
interaction between these polypeptides.
We then analyzed the dependence of the GA 20 and PR20 complex on chemical
factors such as pH. First, we monitored aggregation of both polypeptides individually
and as a mixture by dynamic light scattering over the 2-10 pH range. Dynamic light
scattering data showed that GA 20 is highly aggregation prone at pH 3 while PR20 does
not aggregate (Figure 2.5D; red and blue lines, respectively). Co-incubation of these
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polypeptides resulted in the shift of the aggregation optimum from pH 3 to physiological
pH (pH 6-8) (Figure 2.5D; purple line), an indication of direct interaction between the
polypeptides. We then examined if secondary structure formation was altered across
the same pH range. We recorded the far-UV CD spectra of either the individual
polypeptides or the combined GA 20 and PR20 in solutions with a pH range of 2-10.
Similar to our observations at physiological pH, we found that the spectrum of GA20 has
a negative band at 215-217 nm typical for β-sheet-rich structures with minimal
alterations occurring across the pH range (Figure S2.1A) PR20 maintained a minimum
around 198-200 nm across pH range (Figure S2.1B). The mixture of GA 20 and PR20
demonstrated no structural changes at low pH values (pH 2-4). However, at higher pH
values (pH 6-10), we observed a loss of β-sheet structure and the appearance of
disordered structure as indicated by characteristic changes in the far-UV CD spectra
(Figure 2.5E).
An additional measure of protein structure is intrinsic fluorescence of aromatic
residues [128]. The addition of tryptophan (Trp) residues near the C-terminus allowed
us to examine intrinsic fluorescence as a measure of the hydrophobicity of the
polypeptide at different pH values (schematically represented in Figure 2.6). We found
that the Trp environment in PR20 was hydrophilic at all pH values (em 349 nm), whereas
the Trp environment in GA 20 was moderately hydrophobic (em 339 nm) at pH below 4
and became less hydrophobic (em ~343 nm) at higher pH values (Figure 2.5F). We
generated a calculated fluorescent value for the Trp environment of a mix of GA and PR
(em ~345 nm; Figure 2.5F, dashed line). Interestingly, the measured Trp environment
from the 1:1 mix of GA 20 and PR20 became steadily more hydrophobic with increasing
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pH; distinct from the mathematically averaged em values (Figure 2.5F). These data
suggest the interaction between GA 20 and PR20 produces a distinct secondary or tertiary
structure, not observed with either GA 20 or PR20 independently.
We also assessed if the structures formed by GA 20 and PR20 are dependent on
physiological salt concentrations. We again monitored the Trp environment in the
polypeptides over a 2-10 pH, now in the absence of salt. Similar to conditions with
physiological salt concentrations (see: Figure 2.5F), we found that PR20 was fairly
hydrophilic over the pH range (em 349 nm). GA20 was hydrophobic (em 339 nm) below
pH 4, but loses hydrophobicity (em ~343 nm) at higher pH values (Figure 2.5G). We
found that the co-incubation of GA 20 and PR20 produced a Trp environment intermediate
to those observed in GA 20 and PR20 individually (em ~345 nm), and the environment
became more hydrophobic when pH values increased (Figure 2.5G). We again
compared the calculated average of em values of each polypeptide and saw that it
diverged from the values measured for the GA 20-PR20 mixture, indicating the formation
of a distinct structure when the polypeptides are present at physiological pH values
(Figure 2.5G).
Since both GA 20 and PR20 contain Trp residues, the extent of contribution of each
of these polypeptides to the observed change in Trp environment hydrophobicity is not
immediately obvious. To investigate it further and validate our method, we incubated
GA20 with high molecular weight poly-lysine (poly-K). Though poly-K is not a perfect
mimic of PR20, we anticipate the poly-K/GA20 interaction to present similarly to GA 20 and
PR20 due to the highly positively charged nature and polarity of poly-K. Additionally,
poly-K doesn’t contain aromatic residues; thus, any changes in the fluorescence
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emission wavelength are specific to GA 20. We observed no significant change in Trp
emission wavelength upon addition of poly-K to GA20 (Figure 2.5G). This indicates that
the secondary and tertiary structures adopted by GA and PR following incubation are
unique to these peptides and are not a generic structural state which occurs when GA is
present with positively charged peptides. Together, these results suggested that the
interaction between GA 20 and PR20 results in the formation of a structure that is unique
to the complex between these two DPR species and is dependent on salt and pH
conditions.
2.5

Discussion
In this study we identified a unique interaction between GA and PR which

presents dramatic effects on cell health and stress pathways. Though PR50 presented
as the most cytotoxic DPR species, co-expression with GA 50 abrogated this toxicity. An
examination of the interaction occurring between recombinant and synthesized PR and
GA polypeptides demonstrated a clear interaction presenting distinct and discrete
structural, biophysical, and morphological properties, as well as an increased
aggregation propensity. Taken together, these results indicate that the simultaneous
expression of multiple DPR species influence the cytotoxic output of cells in ALS/FTD
patients with the C9 expansion mutation.
In previous studies it has been shown that PR has a strong proclivity for
interacting with proteins that contain low complexity domains (LCD) [129, 130]. Low
complexity domains are extremely abundant in eukaryotes and are generally composed
of amino acid repeats [131]. The promiscuity of binding exhibited by PR to LCDcontaining proteins has been hypothesized to interfere with several aspects of cellular
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functioning causing alterations in homeostasis and cytotoxicity [130]. Proteomic analysis
of PR showed that it was able to interact with ALS associated proteins FUS, hnRNPA1,
and hnRNPA2B1 [115, 129], all of which contain LCDs thought to mediate assembly
into higher ordered structures such as liquid droplets [132]. Furthermore, it has been
shown that the binding of PR to LCDs stabilizes these structures [115, 129].
Interestingly, ALS associated mutations in these proteins have also been shown to lead
to the stability of higher ordered structures and an increase in membrane-less
organelles such as stress granules [20, 73, 133]. The main mutations associated with
ALS/FTD have convergence based on ability to modify properties of membrane-less
organelles such as stress granules. The ratio of expressed DPRs can modify this.
GA, similar to other ALS pathogenic proteins, can be considered as a low
complexity sequence due to its repeated glycine and alanine residues. The chemical
nature of the amino acid repeats in GA is somewhat like that contained in the FG
repeats in the LCD domain of Nups. Our studies demonstrated that PR can interact with
GA. When GA and PR interact, there is a morphological change in the peptides that
present as spherical liquid-like or highly aggregated higher ordered structures. Since PR
binding to LCDs of ALS related proteins promotes the stabilization of higher ordered
structures such as liquid droplets and dense aggregates, it is conceivable that the
interaction between PR and GA promotes a stabilized higher-order structure that
sequesters the toxic PR, and GA, species; preventing the toxicities associated with
either individual DPR. These stabilized higher-order structures containing GA and PR
may have an increased ability to be recognized and cleared by the cell, possibly through
autophagy; however, additional studies are necessary to confirm this hypothesis.
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Collectively, our results indicate that the specific DPR species being expressed in
a cell, as well as the ratio between different species expressed simultaneously may
influence the cytotoxic output of cells in ALS/FTD patients with the C9 expansion
mutation. Therefore, further work needs to be done to explore which specific ratios may
be exploited to induce or attenuate DPR mediated cytotoxicity and through what
mechanism that is occurring by. By elucidating this fact, there will be a clearer pathway
for therapeutic developments since the phenomenon of simultaneous DPR expression
has been shown to occur in patient tissue.
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Figure 2.1 Schematic showing how the expansion mutation in C9orf72 can lead to
toxicity. The potential mechanisms for pathology are shown in red.
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Figure 2.2 DPR Localization and Toxicity (A) NSC34 cells were transfected with 50repeat GFP-tagged DPR plasmids for 72 hours, with Alamar Blue being added for the last
4 hours. Absorbance readings taken at 570nm showed that PR50 significantly reduced
cell viability and/or cell growth (mean +/- SEM, ANOVA with Tukey tests, *P≤ 0.05, ***P≤
0.001; n=3). (B) Co-transfection of varying amount of PR50 with 250ug of GA 50 in the same
Alamar Blue assay as that listed above, resulted in a rescue of cell viability and/or growth
compared to PR50 expression alone at specific ratios (mean +/- SEM, ANOVA with Tukey
tests, *P≤ 0.05; n=3). (C) NSC34 cells were transfected with 50-repeat GFP-tagged GA
or 50-repeat mCherry-tagged PR for 48 hours then fixed, stained, and imaged. Scale bar
10µm. (D) Quantification of the nuclear/cytoplasmic ratio of PR50 in the NSC34 cells
showed that localization changes to be less nuclear when co-expressed with GA 50 (mean
+/- SEM, t-test, P=0.0048; n=12).
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Figure 2.3 GA Rescues PR Induced Increases in pPERK (A) NSC34 cells were
transfected with GFP-tagged 50-repeat DPR plasmids for 48 hours and the levels of
PERK phosphorylation were measured by immunoblotting. (B) Quantitation showed that
PR50 significantly increases PERK phosphorylation, while the others did not have an
effect (mean +/- SEM, ANOVA with Tukey tests, *P≤ 0.05; ***P≤ 0.001; n=2). (C) Primary
murine neurons were transfected with the same plasmids listed above individually and
co-transfected with GA 50 and PR50. They were then immunostained for phosphorylated
PERK. Scale bar 10nm. (D) The quantitative analysis of PERK levels showed PR 50
significantly increased levels, but this was rescued by co-transfection with GA 50 (mean
+/- SEM, ANOVA with Tukey tests, **P≤ 0.01; ***P≤ 0.001; n=11).
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Figure 2.4 GA Rescues PR Induced Increases in Stress Granule Formation (A)
NSC34 cells were transfected with GFP-tagged 50-repeat DPR plasmids for 48 hours and
the levels of TIA-1 were measured by immunofluorescence. (B) Quantitation showed that
PR50 significantly increases the number but not size of TIA-1 positive stress granules, and
co-transfection of GA 50 rescues this effect (mean +/- SEM, ANOVA with Tukey tests,
***P≤ 0.001; n=2).
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Figure 2.5 GA and PR Interaction Characterization (A) Transmission electron
microscopy was used to visualize recombinant 50-repeat GA, PR, and the combination.
Images revealed that upon co-incubation of recombinant GA 50 with PR50 there was a
dramatic structural change. Scale bar 100nm. (B) Isothermal titration calorimetry was
utilized to evaluate direct binding of GA with PR. 10µM of GA 20 in PBS was placed in a
sample cell of the VP-ITC calorimeter and a 20µM solution of PR20 in PBS was injected
(19 injections, 15µl each) while ITC measurements were performed. After the run was
complete the data was analyzed using Origin software. It revealed that the polypeptides
interacted at a GA to PR ratio of 5:1 in the presence of 150mM NaCl at pH 7.4. (C) 20repeat GA-Flag, PR-HA, or a combination were fixed, immunostained with HA and Flag,
and imaged. Imaging showed that upon co-incubation the polypeptides are more
aggregation prone and colocalize in-vitro (Rcoloc=0.830). Scale bar 10µm.
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Figure 2.6 Physical Properties of GA and PR Interaction (A) Light scattering intensity
of GA20 and PR20 incubated either individually or in combination (0.1 mg/ml) at 25°C at
pH 7.0 in the presence of 0.15 M NaCl. (B) Nanoparticle tracking analysis of GA20 and
PR20 polypeptides incubated either individually (0.1 mg/ml) or in combination at 25°C at
pH 7.5. Red-GA20; blue-PR20; purple-1:1 mixture of GA 20 and PR20. (C) Far UV CD spectra
of GA20 (red line), PR20 (blue line), and their mixture (purple line) at pH 7.5 in the presence
of 0.15 M NaCl. (D) Light scattering intensity of GA 20 and PR20 incubated either
individually or in combination (0.1 mg/ml) at 25 °C at different pH values. Red–GA20; bluePR20; purple-1:1 mixture of GA 20 and PR20. (E) Far UV CD spectra of combined GA and
PR peptides at different pH values. (F) Intrinsic fluorescence emission wavelength of GA 20
and PR20 incubated individually or in combination (0.025 mg/ml) at 25 °C at different pH
values in the presence of 0.15 M NaCl. Red–GA20; blue-PR20; purple-1:1 mixture of GA 20
and PR20; black–an average of intrinsic fluorescence emission wavelengths of GA 20 and
PR20. (G) Intrinsic fluorescence emission wavelength of GA 20 and PR20 polypeptides
incubated either individually or in combination (0.025 mg/ml) at 25 °C at different pH
values. Red–GA20; blue-PR20; purple-1:1 mixture of GA 20 and PR20; black–an average of
intrinsic fluorescence emission wavelengths of GA 20 and PR20, green–1:1 mixture (by
weight) of GA 20 and poly-K.
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Figure 2.7 Schematic of the proposed tryptophan (W) environment in the different
conditions. With GA20 only the tryptophan is buried in a hydrophobic environment while
in PR20 only it is freely interacting with the aqueous environment. Upon interaction of the
two peptides, the tryptophan in PR20 becomes more buried and the environment more
hydrophobic.
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Figure S2.1 CD spectra of GA and PR at different pHs (A) Far UV CD spectra of
GA20 at a 2-10 pH range. (B) Far UV CD spectra of PR20 at the same pH range.
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Chapter Three:
Protein Aggregation and Liquid-Liquid Phase Separation in Alzheimer’s Disease
3.1 Abstract
Alzheimer’s disease (AD) is a progressive fatal neurodegenerative disease with
no cure. The hallmarks of disease include extracellular protein plaques and intracellular
tangles of aggregated protein. The intracellular tangles consist of the microtubule
associated protein tau (MAPT, tau). Preventing the pathological aggregation of tau may
be an important therapeutic approach to treat disease. In this study we show that small
heat shock proteins, specifically heat shock protein 22kDa (Hsp22), can prevent the
aggregation of tau in-vitro. Additionally, we show that tau can undergo liquid-liquid
phase separation which causes it to have an increased aggregation rate and reduced
dynamics. We demonstrate that Hsp22 can impact the aggregation and behavior of
phase separated tau.
3.2 Introduction
Tau aggregation is a hallmark in AD and promotes neuronal loss and cognitive
decline [134-138]. Additionally, there are several other neurodegenerative disorders that
are characterized by the aberrant aggregation of tau referred to as tauopathies such as
progressive supramolecular palsy and frontotemporal dementia [139, 140]. When tau
aggregates it forms a structure distinguished by β-sheets that can form long fibers that
promote misfolding of other protein species known as amyloid [141]. While it has long
been recognized that hyperphosphorylation of tau can cause it to dissociate from
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microtubules and facilitate self-interaction which can lead to aggregation [142], the
exact mechanism that causes tau to become pathological has remained enigmatic.
However, strategies to reduce tau aggregation and increase degradation of aberrant
species have been shown to be effective in restoring cognitive decline in AD mouse
models and cellular functioning [143, 144].
One strategy that has been used is to increase the expression of chaperone
proteins which are involved in maintaining cellular proteostasis [145-150]. Depending on
the chaperone protein, they can lead to an increase or decrease in tau loads [145, 146,
148-151]. Additionally, modifications of chaperones can cause them to have an
increased ability to chaperone tau or conversely lose the ability altogether [151].
Studies using the small heat shock chaperone protein (sHsps) heat shock protein
27kDa (Hsp27) have demonstrated the dramatic effect that chaperone modifications
can have on functioning by comparing the activity of WT Hsp27 to a perpetually
pseudophosphorylated mutant 3xS/D Hsp27 [151]. Data showed that while both
versions were able to prevent tau aggregation in-vitro, WT Hsp27 was able to reduce
tau levels and restore loss in long term potentiation in a tau mouse model while 3xS/D
Hsp27 increased tau levels and did not restore long term potentiation [151]. This study
demonstrated that the dynamic ability of sHSPs like Hsp27 to be phosphorylated is
important for their chaperone activity towards client proteins such as tau. In this study,
we wanted to test a similar sHSP, heat shock protein 22kDa (also referred to as
HSPB8), to see if it could also prevent tau aggregation in-vitro.
In addition to tau hyperphosphorylation driving aggregation, it was recently
discovered that tau can undergo LLPS which can initiate its aggregation and cause it to
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seed the aggregation of other proteins [77]. In this study we wanted to see if 4R0N WT
tau could undergo LLPS as well as two disease related mutants P301L and ΔK280 tau.
Additionally, we looked at how tau LLPS effects its aggregation behavior and dynamics.
Lastly, since chaperone proteins have an influence on the behavior and structure of tau,
we wanted to see if chaperone proteins, namely Hsp22, could affect the LLPS behavior
of tau.
3.3 Materials and methods
3.3.1 Molecular Cloning
WT tau, P301L tau, ΔK280 tau, Hsp22 WT, Hsp22 3x S/D, and Hsp22 3x S/A
were generated in lab by insertion into a pet28a vector backbone using restriction
enzyme digests followed by ligation.
3.3.2 Protein expression and purification
E. coli BL21 cells were transformed with 4R0N WT tau, 4R0N P301L tau, 4R0N
ΔK280 tau, WT Hsp22, S/A Hsp22, and S/D Hsp22 plasmids in a pet28a vector with a
6x histidine tag and TEV protease site. The cells were then grown at 37°C in LB media
containing 100 μg/mL kanamycin. Once their OD600 reached 0.8 the cells were induced
with 1mM of IPTG (Gold Biotechnology, Olivette, MO) for 3 hours. Centrifugation at
5,000 g for 15 min was used to harvest the cells, which were then resuspended with
nickel chromatography running buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM
Imidazole) containing protease inhibitors. The cells were then lysed using a freeze-thaw
cycle followed by sonication. The lysed cells were centrifuged at 50,000 g for 1 hour at
4°C. The supernatant was affinity purified using a standard gravity column packed with
HisPur™ Ni-NTA Resin (Fisher Scientific, Waltham, MA). The eluted fractions were

57

treated with TEV protease for 4 hours at room temperature then dialyzed back into
nickel chromatography running buffer overnight. A second nickel purification column
was run and the efficiency of the TEV cleavage was assessed by SDS-PAGE followed
by Coomassie staining. For the tau constructs, size exclusion chromatography was
performed using a HiLoad 16/600 Superdex 200pg column. Fractions containing >95%
pure tau were pooled and concentrated. The concentrated protein was then aliquoted,
flash frozen with liquid nitrogen, and frozen at -80ºC until use.
3.3.3 Fluorescently labeling recombinant proteins
An Alexa Fluor® 488 protein labeling kit (Fisher, Cat# A10235/A10239) was used
to label recombinant proteins. Briefly, recombinant proteins were concentrated into 1mL
at a concentration of 10mg/ml. They were then dialyzed into 100mM sodium
bicarbonate buffer pH 8 overnight. Following dialysis, 1 vial of reactive dye was added
to 1mL of protein and allowed to react at 37 degrees for 1 hour. After 1 hour, the
reaction was quenched by adding 100uL of 100mM glycine buffer pH 8. The proteins
were then subjected to 10 rounds of buffer exchange into 50mM sodium phosphate pH
8 to get rid of residual dye. The degree of labeling was determined by measuring the
absorbance of the conjugate solution at 280nm and 494nm in a cuvette with a 1cm
pathlength.
3.3.4 Thioflavin T fluorescent assays
Recombinant tau and Hsp22 proteins were dialyzed into 100mM sodium acetate
buffer pH 7 overnight. 20uM of P301L or ΔK280 tau or 10uM of WT tau was mixed with
varying amounts of WT Hsp22, S/A Hsp22, or S/D Hsp22 as well as 10uM heparin and
10uM thioflavin T. 100uL of each condition was loaded onto 96-well black clear-bottom
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plates (Fisher, Cat#07-200-525) in triplicate. Fluorescence was then read at 440nm
excitation and 482 nm emission every 10 minutes over a 72-hour period using a BioTek
Synergy H1 plate reader.
3.3.5 Transmission electron microscopy
10uL of the end products of the thioflavin T assay were adsorbed onto
prewashed 200 mesh formvar/carbon-coated copper grids for 5 min. The grids were
washed with water (10 μl) two times, stained with filtered 2% uranyl acetate (10 µl) for 1
minute, then dried. The samples were analyzed with a JEOL 1400 Digital Transmission
Electron Microscope, and images were captured with a Gatan Orius wide-field camera
at the Electron Microscopy Core Facility in the College of Medicine at the University of
South Florida.
3.3.6 Liquid droplet formation and visualization
Recombinant tau protein was dialyzed into 50mM sodium phosphate buffer pH 8
overnight. Droplet formation was induced by using either 10% polyethylene glycol,
12.5% ficoll, or 12.5% dextran in the presence of 1mM DTT. Tau droplets were
observed with an EVOS fluorescent microscope using the visible light and fluorescence
channels.
3.3.7 Turbidity assays
Tau turbidity was measured using absorbance at 350nm and was performed
using a BioTek Synergy H1 plate reader.
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3.3.8 Fluorescent recovery after photobleaching
A 488nm laser line of a confocal ZEISS LSM 880 (Confocal Laser Scanning
Microscope) with Airyscan was used on a 1µm diameter spot on tau droplets at 100%
transmission for 5 seconds. Pre-bleached and post-bleached images were captured.
3.3.9 Image analysis and statistics
Quantitative analysis of the tau droplet number and size was performed using
ImageJ software (National Institutes of Health). The statistical significance performed for
each analysis was done using unpaired t-tests. Statistical analysis was performed using
the GraphPad Prism version 5.02 software.
3.4 Results
3.4.1 Hsp22 prevents tau aggregation in-vitro
To investigate the role that Hsp22 has on tau aggregation, we first purified WT
Hsp22 and two genetically altered versions, 3X S/D which is perpetually pseudophosphorylated and 3X S/A which is unable to be phosphorylated. Additionally, we
purified three different versions of tau, WT tau, P301L tau, and ΔK280 tau. In order to
investigate whether tau aggregation could be altered by Hsp22, we conducted a
thioflavin T assay and subsequently imaged the end products using transmission
electron microscopy (TEM). Tau was induced to aggregate with heparin and
aggregation was followed over a 72-hour period taking readings every 10 minutes.
Results showed that all 3 versions of Hsp22 were able to reduce aggregation of all
versions of tau tested (Figure 3.1A).
We then further characterized the aggregation of the final ThT products by
visualizing them using TEM. Results showed that all 3 version of tau formed large fibril
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structures, and all versions of Hsp22 were able to dramatically reduce the size of those
fibrils. It should be noted that in the Hsp22 conditions, tau fibrils were still present but
the size, specifically the width of fibrils, was reduced (Figure 3.1B). Taken together,
these data indicate that Hsp22 can prevent the aggregation of WT tau and disease
related mutants P301L and ΔK280.
3.4.2 Tau phase separates in-vitro
To determine if tau was able to undergo LLPS, we used crowding agents to
induce the process. Fluorescently labeled (488nm) WT tau, P301L tau, and ΔK280 tau
were mixed with 10% polyethylene glycol, the crowding reagent, and were then
visualized via microscopy both in the visible light spectra as well as by fluorescent
visualization. Results showed that all 3 versions of tau were able to efficiently undergo
phase transition into droplet like structures (Figure 3.2A). Additionally, to ensure phase
separation had occurred, we took absorbance readings at 350nm which should increase
if a protein undergoes a phase transition. Results demonstrated that all 3 versions of tau
had a dramatic increase in turbidity upon formation of droplets in solution (Figure 3.2B).
These results indicate that WT tau and disease related mutants can undergo LLPS invitro in the presence of crowding agents.
3.4.3 Tau phase separation causes an increase in aggregation rate
The aggregation behavior of tau was assessed via thioflavin t fluorescence. Tau
with and without 10% PEG was induced to aggregate with 10uM of heparin and
aggregation was monitored via 10uM of thioflavin T over a period of 72 hours with
readings taken every 10 minutes. Results showed that phase separated P301L tau has
an increased rate of aggregation and produces more thioflavin T reactive species as
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compared to tau that is not phase separated (Figure 3.3). These results are not
surprising since phased separated proteins are forced it into a more confined area
where it they have a higher probability to self-interact.
3.4.4 Phase separated tau loses dynamics
In order to measure the dynamics of in-vitro phase separated tau we used
turbidity readings over time as well as fluorescent recovery after photobleaching
(FRAP). Initial turbidity readings of P301L tau showed a dramatic increase in turbidity,
but that was steady over a time of 72 hours (Figure 3.4B). Because there was no
change in turbidity, it can be assumed that tau phase separation occurs immediately,
and the behavior does not increase over time.
To look more carefully at the dynamics of tau droplets, we used FRAP. After
photobleaching, if molecules are dynamic, fluorescence should return to the bleached
area due to diffusion. We bleached an area on P301L tau droplets and monitored it for
24 hours. In that time, we saw no recovery of fluorescence, indicating a loss of
dynamics in the tau droplets (Figure 3.4A). Additionally, we noticed that the droplets
that were formed on the coverslip used to visualize the protein did not move over time.
This indicated to us that they were no longer dynamic and did not possess liquid like
structures which are able to freely flow and fuse. Taken together, these data indicate
that phase transitioned tau quickly converts to a less dynamic structure. We
hypothesize this is due to tau undergoing a transition from a liquid like state into a gel.
3.4.5 Hsp22 has an impact on phase separated tau
Next, we wanted to see if Hsp22 was able to alter the behavior of tau LLPS since
phase separated tau has an increased aggregation rate. To do that we mixed P301L tau
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with WT Hsp22 at a 20:1 tau:hsp22 ratio and then induced tau phase transition.
Turbidity at 350nm was measured and showed that P301L tau was able to phase
separate in the presence of Hsp22 (Figure 3.5A). The tau droplets were then visualized
by fluorescent microscopy. Results showed that Hsp22 causes a significant increase in
the number of tau droplets (Figure 3.5B). Additionally, tau droplets formed in the
presence of Hsp22 had a trend of being smaller, but it was not a significant result.
We also wanted to see if Hsp22 could alter the increased rate of phase
separated tau aggregation. To do this, we used thioflavin T to measure tau aggregation
induced with heparin over time. We did this in the presence and absence of WT Hsp22.
Results showed that Hsp22 can prevent the increased rate of tau droplet aggregation
and smaller species overall are formed (Figure3.5C). These results show that Hsp22
has an impact on the LLPS behavior of tau in-vitro.
3.5 Discussion
There has been a large level of research aimed at trying to determine tau’s
aggregation kinetics, the structure of tau aggregates, and pathological consequences of
tau in the brain [152, 153]. However, the question of what the early trigger of tau
aggregation remains elusive. Here we show that WT tau and disease relative mutants
(P301L and ΔK280) can undergo LLPS and aggregation can be triggered by this
process. Additionally, we show that tau LLPS leads to the formation and droplets that
lose dynamics.
Physiologically, tau can undergo LLPS to enhance the polymerization of
microtubules by pulling tubulin dimers into the confined space of a droplet and once
polymerization has ensued, tau droplets can dissipate [51]. However, it is possible that
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disease related mutations or pathological phosphorylation can alter the dynamics of tau
droplets and disable them from dissipating. Since that would trap tau in the confined
space of the droplet, it is conceivable that this would seed its aggregation. Therefore,
the mechanisms of physiological tau LLPS should be studied further to see what
aberrations can lead to loss of dynamics and pathological aggregation.
Additionally, since chaperone proteins have been shown to have an effect on tau
aggregation [145, 147, 150], we decided to test the ability of Hsp22 to prevent tau
aggregation in-vitro. Our studies showed that Hsp22 can prevent the aggregation of tau,
both phase-separated and non-phase-separated versions. Since Hsp22 can access
proteins that are in phase separated droplets such as those in stress granules due to its
intrinsically discorded N-terminal domain [58], it is not surprising that it would be able to
access LLPS tau and have a role in its aggregation. Future studies should be aimed at
determining how chaperone proteins such as Hsp22 can prevent the aberrant
aggregation of phase separated tau. This could present as a potential mechanism to
deal with tau aggregation and therefore could be posed as a possible therapeutic option
to treat tauopathies.
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Figure 3.1 Hsp22 WT and mutants prevent tau aggregation in-vitro. (A) Heparin
induced tau aggregation was measured over 72 hours for thioflavin T (ThT)
fluorescence (ex/em 448/482nm) and the endpoint ThT RFU values were normalized to
tau by itself and plotted (bars represent SEM, unpaired t-test, p-values shown, n=3).
Representative 20,000x transmission electron microscopy images of the ThT endpoint
tau fibrils alone and incubated with Hsp22 at a 20:1 tau:Hsp22 ratio (scale bar=1uM).
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Figure 3.2 WT tau and disease relevant mutants undergo LLPS. Fluorescently
labeled tau was induced to undergo LLPS with 10% polyethylene glycol. (A) Fluorescent
images were captured to show the tau droplets that were formed. (B) The turbidity
(absorbance at 350nm) was measured for tau with and without 10% PEG. (bars
represent SEM, unpaired t-test, n=3).
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Figure 3.3 Phase separated P301L tau has an increased rate of aggregation.
Heparin induced P301L tau aggregation was measured in the absence and presence of
a crowding agent, which induced tau droplet formation over 72 hours. Thioflavin T (ThT)
fluorescence (ex/em 448/482nm) was measured and the endpoint ThT RFU values
were plotted (bars represent SEM, unpaired t-test, p-values shown, n=2) as well as the
aggregation rate over time.
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Figure 3.4 Phase separated P301L tau loses dynamics. (A) P301L tau droplets
labeled with Alexa fluor-488 were subjected to bleaching in a spot with a diameter of
1µm. From 30 seconds after bleaching to 24 hours later, there was no fluorescent
recovery in the area that was photobleached and the droplets did not change location.
(B) The turbidity (absorbance at 350nm) of phase-separated tau was compared to that
of non-phase-separated tau over a 96-hour period. When tau phase separated, the
turbidity had a drastic immediate increase. However, over time the turbidity remained
constant.
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Figure 3.5 Hsp22 WT changes the characteristics of tau droplets. (A) The turbidity
(absorbance at 350nm) was measured for phase separated tau with and without Hsp22
(error bars represent SEM). (B) 488-labeled P301L tau droplets were visualized with
fluorescent microscopy in the presence of absence of Hsp22 WT. Quantification of
droplets size and number showed that Hsp22 significantly increase the number of
phase separated tau droplets and had a trend (non-significant) of decreasing their size
(bars represent SEM, unpaired t-test, p-values shown, n=3). (C) Thioflavin T
fluorescence of phase separated tau with and without Hsp22 was measured over 72
hours and the endpoint ThT values were plotted (bars represent SEM, unpaired t-test,
n=3).
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Chapter Four:
Overall Conclusions and Future Studies
4.1 Overall Conclusions
Within the work of this manuscript we provide evidence that protein LLPS is a
key element in neurodegenerative diseases. We showed that in AD and ALS/FTD,
there are intrinsically disordered proteins that undergo phase separation, and this
causes problems in cellular functioning and pushes proteins towards pathological
aggregation. Additionally, we demonstrated that there are ways to modulate this
behavior.
To modulate LLPS behavior in ALS/FTD, the ratio of dipeptide repeat proteins
derived from the C9orf72 hexanucleotide repeat expansion can be altered. We showed
that if you express GA and PR at a 5:1 ratio of GA:PR it can have a protective role in
the cell and reduce aberrant LLPS seen in the form of stress granule assembly.
Therefore, this finding could be exploited to alter the aberrant phase separation
behavior in the cell, something that is a hallmark of ALS/FTD [30].
Similarly, there are ways to modulate the behavior of protein LLPS in AD. Here,
we showed that Hsp22 can prevent tau aggregation of both LLPS tau and tau that is not
phase separated. Additionally, we show that Hsp22 can influence the number of tau
droplets formed as well as their size. Because of this, chaperone proteins should be
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further explored for activity involved in modulating the LLPS behavior of proteins
involved in neurodegenerative diseases.
4.2 Future Studies
To examine how protein LLPS can lead to pathological effects on the cells,
methods should be used to induce LLPS in a more physiological setting. One proposed
method is using optogenetics. By using cytochrome2 (cry2), a protein derived from
Arabidopsis Thaliana, it is now possible to study this. Cry2 oligomerizes upon exposure
to blue light [154]. Therefore, plasmid constructs could be engineered that contain the
protein of interest with Cry2 [154]. By doing that, blue light exposure could be used to
induce LLPS in a cell, either transfected with the plasmid or engineered to stably
express it, at specific times and specific locations [154]. This would enable one to study
the dynamics of protein LLPS and how disease relevant mutations could alter those
dynamics in a more physiological setting without using crowding reagents.
Additionally, since there is a way to modulate protein LLPS in ALS/FTD by
exploiting the ratio of DPRs expressed, more studies should be conducted to further
examine how GA may perturb the phase transition of arginine rich DPRs in-vitro and
more in-depth analysis should be done on how this impacts the physiological
functioning in the cell. Also, other combinations and ratios of DPRs should be tested to
see if there are similar effects with other combinations.
Furthermore, since chaperone proteins have long been used to alter the protein
folding activity of proteins as well as their degradation [147], they would be an
interesting target to test to see how they could affect protein LLPS and subsequent
aggregation. Because chaperone proteins have been shown to have opposing effects
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on tau aggregation, it would be interesting to test these same chaperones with LLPS tau
to see if they could alter the LLPS behavior or aggregation. Also, chaperone protei ns
could be tested with other proteins involved in neurodegenerative diseases that are
known to undergo LLPS such as the arginine rich DPRs.
Determining the very initial steps that seed the aggregation of pathological
proteins found in neurodegeneration will be key to prevent downstream aggregation.
However, once the initial steps are determined, there must be a strategy to modulate
this behavior. Exploiting protein ratios and adding in chaperone proteins may serve as
a therapeutic route to modulate LLPS and potentially prevent subsequent pathological
aggregation in neurodegenerative diseases.
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